Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
294 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape. Relapsed chronic lymphocytic leukemia (CLL) is a type of cancer chronic lymphocytic leukemia, that the cancer has come back after remission was achieved with treatment. Symptoms include weakness, feeling tired, weight loss, fever, night sweats and enlarged lymph nodes, pain or a sense of fullness in the belly which is caused by an enlarged spleen. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 21, 20 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Relapsed Chronic Lymphocytic Leukemia (CLL). Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology). - The pipeline guide reviews pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9 Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17 Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20 Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21 4SC AG 21 AbbVie Inc 22 Aptevo Therapeutics Inc 23 Astellas Pharma Inc. 24 Astex Pharmaceuticals Inc 25 Boehringer Ingelheim GmbH 26 Bristol-Myers Squibb Company 27 Celgene Corporation 28 Cellular Biomedicine Group, Inc. 29 Cyclacel Pharmaceuticals, Inc. 30 F. Hoffmann-La Roche Ltd. 31 Gilead Sciences, Inc. 32 Hutchison MediPharma Limited 33 ImmunoGen, Inc. 34 Immunomedics, Inc. 35 Incyte Corporation 36 Innate Pharma S.A. 37 Juno Therapeutics Inc. 38 Karyopharm Therapeutics, Inc. 39 LFB S.A. 40 Lymphocyte Activation Technologies, S.A. 41 Millennium Pharmaceuticals Inc 42 MorphoSys AG 43 Novartis AG 44 Oncternal Therapeutics, Inc. 45 Ono Pharmaceutical Co., Ltd. 46 PIQUR Therapeutics AG 47 Rhizen Pharmaceuticals S.A. 48 Sanofi 49 TRACON Pharmaceuticals Inc 50 Tragara Pharmaceuticals, Inc. 51 Verastem, Inc. 52 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 53 Assessment by Monotherapy Products 53 Assessment by Combination Products 54 Assessment by Target 55 Assessment by Mechanism of Action 58 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 (dezapelisib + itacitinib adipate) - Drug Profile 65 4SC-202 - Drug Profile 66 acalabrutinib - Drug Profile 68 ACP-319 - Drug Profile 71 afuresertib hydrochloride - Drug Profile 72 AGS-67E - Drug Profile 75 AT-7519 - Drug Profile 77 atezolizumab - Drug Profile 80 BI-836826 - Drug Profile 94 BMS-986016 - Drug Profile 96 buparlisib hydrochloride - Drug Profile 98 CBM-C19.1 - Drug Profile 103 CC-122 - Drug Profile 104 Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 106 Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 107 duvelisib - Drug Profile 108 HMPL-523 - Drug Profile 119 idelalisib - Drug Profile 121 IMGN-529 - Drug Profile 129 IMMU-114 - Drug Profile 131 JCAR-014 - Drug Profile 133 JCAR-015 - Drug Profile 136 lirilumab - Drug Profile 141 monalizumab - Drug Profile 145 MOR-208 - Drug Profile 148 nivolumab - Drug Profile 153 obinutuzumab - Drug Profile 182 ofatumumab - Drug Profile 189 otlertuzumab - Drug Profile 197 PCAR-019 - Drug Profile 200 PCAR-119 - Drug Profile 201 pilaralisib - Drug Profile 202 PNK-007 - Drug Profile 204 PQR-309 - Drug Profile 205 S-055746 - Drug Profile 207 sapacitabine - Drug Profile 208 selinexor - Drug Profile 214 spebrutinib besylate - Drug Profile 233 TAK-659 - Drug Profile 235 TG-02 - Drug Profile 236 TGR-1202 - Drug Profile 239 tisagenlecleucel-T - Drug Profile 246 TRC-102 - Drug Profile 251 ublituximab - Drug Profile 253 UC-961 - Drug Profile 260 ulocuplumab - Drug Profile 262 urelumab - Drug Profile 263 venetoclax - Drug Profile 265 Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 274 Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 276 Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 277 Featured News & Press Releases 277 Appendix 289 Methodology 289 Coverage 289 Secondary Research 289 Primary Research 289 Expert Panel Validation 289 Contact Us 289 Disclaimer 290
List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2016 13 Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Number of Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Comparative Analysis by Late Stage Development, H2 2016 18 Comparative Analysis by Clinical Stage Development, H2 2016 19 Comparative Analysis by Early Stage Development, H2 2016 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Development by Companies, H2 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2016 24 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016 25 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016 26 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H2 2016 27 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2016 28 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 29 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 30 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016 31 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2016 32 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 33 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 34 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 35 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2016 36 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2016 37 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2016 38 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2016 39 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2016 40 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H2 2016 41 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2016 42 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 43 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2016 44 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016 45 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 46 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016 47 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016 48 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016 49 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 50 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H2 2016 51 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 52 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016 53 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 54 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 55 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem, Inc., H2 2016 56 Assessment by Monotherapy Products, H2 2016 57 Assessment by Combination Products, H2 2016 58 Number of Products by Stage and Target, H2 2016 60 Number of Products by Stage and Mechanism of Action, H2 2016 63 Number of Products by Stage and Route of Administration, H2 2016 66 Number of Products by Stage and Molecule Type, H2 2016 68 Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016 278 Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016 279 Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016 280
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
